MUMS (Minor Use Major Species) Status secured for new pipeline product in the US and Europe

TriviumVet have received MUMS status for a new product in both the US and EU markets. The molecule is an exciting therapeutic which will have a big impact on the quality of life of pets across the US and European market. Clinical trials are set to commence in Q3 2020.

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest